The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells

被引：47

作者：

Sakurai, Toshihiko ^{[1
]}

Bilim, Vladimir N. ^{[1
]}

Ugolkov, Andrey V. ^{[3
]}

Yuuki, Kaori ^{[1
]}

Tsukigi, Masaaki ^{[1
]}

Motoyama, Teiichi ^{[2
]}

Tomita, Yoshihiko ^{[1
]}

机构：

[1] Yamagata Univ, Sch Med, Dept Urol, Mol Oncol Lab, Yamagata 9909585, Japan

[2] Yamagata Univ, Sch Med, Dept Human Pathol, Dept Pathol 2, Yamagata 9909585, Japan

[3] Northwestern Univ, Chem Life Proc Inst, Ctr Dev Therapeut, Evanston, IL USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2012年 / 422卷 / 04期

基金：

日本学术振兴会;

关键词：

Renal cell carcinoma; Enhancer of zeste homolog 2; MicroRNA-101; GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE; DNA METHYLATION; CARCINOMA; PROLIFERATION; EXPRESSION; GENE; OVEREXPRESSION; PROGRESSION; ROLES;

D O I：

10.1016/j.bbrc.2012.05.035

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation. (C) 2012 Elsevier Inc. All rights reserved.

引用

页码：607 / 614

页数：8

共 31 条

[1] Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma [J].

Avissar-Whiting, Michele ;

Koestler, Devin C. ;

Houseman, E. A. ;

Christensen, Brock C. ;

Kelsey, Karl T. ;

Marsit, Carmen J. .

EPIGENETICS, 2011, 6 (06) :703-709

[2] Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions [J].

Bracken, AP ;

Dietrich, N ;

Pasini, D ;

Hansen, KH ;

Helin, K .

GENES & DEVELOPMENT, 2006, 20 (09) :1123-1136

[3]

Bukowski R M, 2001, Semin Urol Oncol, V19, P148

[4]

Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO

[5]

2-H

[6] Systemic therapy for metastatic renal cell carcinoma in treatment naive patients: a risk-based approach [J].

Bukowski, Ronald M. .

EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) :2351-2362

[7] The role of EZH2 in tumour progression [J].

Chang, C-J ;

Hung, M-C .

BRITISH JOURNAL OF CANCER, 2012, 106 (02) :243-247

[8]

Di Fiore F., 2012, BRIT J CANCER, V109, P1349

[9] Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis [J].

Fluge, O. ;

Gravdal, K. ;

Carlsen, E. ;

Vonen, B. ;

Kjellevold, K. ;

Refsum, S. ;

Lilleng, R. ;

Eide, T. J. ;

Halvorsen, T. B. ;

Tveit, K. M. ;

Otte, A. P. ;

Akslen, L. A. ;

Dahl, O. .

BRITISH JOURNAL OF CANCER, 2009, 101 (08) :1282-1289

[10] Oxidative stress, DNA methylation and carcinogenesis [J].

Franco, Rodrigo ;

Schoneveld, Onard ;

Georgakilas, Alexandros G. ;

Panayiotidis, Mihalis I. .

CANCER LETTERS, 2008, 266 (01) :6-11

← 1 2 3 4 →